The vast majority of patients treated prophylactically with "first-line" antiemetics in the 5-hydroxytryptamine (5-HT3) receptor antagonist class still have significant PONV. Combination therapies with different pharmacologic bases have the potential to reduce the incidence of PONV. This study is a multicenter, three-arm, prospective study to evaluate the efficacy and safety of aprepitant and ondansetron, monotherapy or in combination, in the prevention of nausea and vomiting after surgery for thyroid cancer.

开始日期2024-12-01

申办/合作机构

郑州大学第一附属医院

NCT06543966

/ Not yet recruiting临床3期

A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Aprepitant Injection in the Prevention of Post-operative Nausea and Vomiting

A randomized, double-blind, placebo-controlled, multi-center phase III study to compare the efficacy and safety of aprepitant injection and placebo in the prevention of post-operative nausea and vomiting (PONV).,

开始日期2024-10-28

申办/合作机构

石药集团中诺药业（石家庄）有限公司

ChiCTR2400089511

/ Suspended临床1期IIT

Efficacy and safety of Aprepitant and Ondansetron in the prevention of nausea and vomiting after TKA

开始日期2024-09-30

申办/合作机构

山东大学齐鲁医院

100 项与阿瑞匹坦相关的临床结果

登录后查看更多信息

100 项与阿瑞匹坦相关的转化医学

登录后查看更多信息

100 项与阿瑞匹坦相关的专利（医药）

登录后查看更多信息

1,214

项与阿瑞匹坦相关的文献（医药）

2025-01-01·ANESTHESIA AND ANALGESIA

Anesthesia Providers’ Knowledge of Medication Interference with Hormonal Contraception: A Multisite Survey

Article

作者: Whitney, Madeline ; Buckner-Petty, Skye ; Kraus, Molly B. ; Harbell, Monica W. ; Sharpe, Emily E.

BACKGROUND::

Sugammadex, aprepitant, and fosaprepitant are increasingly used perioperatively. These medications may interfere with the effectiveness of hormonal contraception. This study assessed anesthesia providers’ use of sugammadex and aprepitant, their knowledge of interactions with hormonal birth control, and patient counseling practices to identify possible knowledge gaps or opportunities for practice improvement.

METHODS::

In January 2023, an electronic survey was distributed to all anesthesia providers at Mayo Clinic sites (Mayo Clinic Rochester, Mayo Clinic Arizona, Mayo Clinic Florida, and Mayo Clinic Health System hospitals). The survey included 32 questions assessing providers’ use of sugammadex and aprepitant, their knowledge of the medications’ interactions with hormonal contraceptives (HC), their perceptions regarding education of these interactions during training, and their perioperative patient counseling practices. The collected data were analyzed using descriptive statistics.

RESULTS::

A total of 337 of 1092 (31%) providers completed the survey. While almost all respondents (324; 96%) knew that sugammadex may interfere with oral contraceptive effectiveness, only 158 (47%) knew about aprepitant’s potential contraceptive interference. Only 176 providers (52%) knew the recommended duration for alternative contraceptive methods after use after sugammadex, and 119 providers (35%) knew the recommended duration after aprepitant exposure. Most respondents considered the interference of these perioperative drugs with HCs to be clinically relevant (sugammadex, 217, 64%; aprepitant, 191, 58%). Despite the common belief that the decision between these medications and alternatives should be shared between provider and patient, most providers reported rarely engaging in such shared decision-making (SDM) in practice. Most providers recognized the need for preoperative discussions on sugammadex (280, 83%) and aprepitant (257, 76%), yet 184 providers (73%) never or rarely discussed contraception use before surgery for aprepitant, and 135 (36%) never or rarely did so for sugammadex. Lastly, many providers believed that the interference between sugammadex, aprepitant, and HC was poorly taught during training.

CONCLUSIONS::

The results of this study highlight the need for increased education and awareness among anesthesia providers regarding drug interactions with HCs during the perioperative period. To facilitate SDM, it is imperative that providers discuss alternative medications and the potential need for additional contraception methods after drug administration and communicate the risks with patients preoperatively to enable informed and SDM. The patient’s preferences should be accounted for, especially if they are unwilling or unable to use an alternative contraceptive for 7 to 30 days, thereby avoiding the complexities and burdens of altering birth control methods.

2025-01-01·NEUROPEPTIDES

NK1 receptor blockade disrupts microtumor growth and aggregation in a three-dimensional murine breast cancer model

Article

作者: Boada, M Danilo ; Gutierrez, Silvia

Several data indicate that Substance P (SP) neurokinin type 1 receptor (NK1R) is at the center of the interaction between cancer cells and peripheral sensory neurons. Selecting the appropriate cancer cell line and its susceptibility to being modulated by NK1 antagonists are critical to studying this complex interaction. In the current study, we have focused on this selection by comparing several aspects of the triple-negative breast cancer (TNBC) cell line (MDA-MB-231^LUC+) with a modified murine cell line (E0771^LUC+), both expressing luciferase. This comparison was made using several methods, SP stimulation and 3D cell culture models, to better reproduce the heterogenous microenvironment of solid tumors observed in vivo. Furthermore, the susceptibility of the murine cell line (E0771^LUC+) to NK1R antagonist (Aprepitant) was tested. Our results indicate that E0771^LUC+ recapitulates several essential aspects of the human cell line, rendering this murine line ideal to be used on immune-competent animals during in vivo studies. We have also found that both cell lines are susceptible to SP stimulation, and their proliferation is disrupted by NK1R antagonists (Aprepitant). In vivo studies are required to verify and refine these findings.

2024-12-01·LIFE SCIENCES

Repurposing Aprepitant: Can it protect against doxorubicin-induced Chemobrain beyond its antiemetic role?

Article

作者: El-Mokadem, Bassant M ; El-Abhar, Hanan S. ; Gomaa, Asmaa A. ; Abdallah, Dalaal M ; Abdallah, Dalaal M. ; El-Mokadem, Bassant M. ; Gomaa, Asmaa A ; El-Abhar, Hanan S

The substance P (SP) and neurokinin-1 receptor (NK-1R) axis is crucial in numerous pathological processes, including inflammation, stress responses, pain perception, and vomiting. Consequently, aprepitant, an NK-1R blocker, is used as an antiemetic in chemotherapy, including the use of doxorubicin (DOX), but whether aprepitant can also assuage DOX-mediated chemobrain remains to be unveiled. Here, we scrutinized the potential neuroprotective effect and underlying mechanisms of aprepitant using DOX-induced chemobrain model, where rats were allocated into 4 groups (control, aprepitant, DOX, and DOX+ aprepitant). Cognitive deficits were assessed through behavioral tests and hippocampal structural alterations were determined by H&E and toluidine blue staining. Biochemical measurements were performed using ELISA, real-time quantitative PCR, western blotting, and immunohistochemical methods. Aprepitant improved cognitive responses, and hippocampal morphology, enhancing the presence of intact neurons. At the molecular tier, aprepitant significantly reduced hippocampal contents of SP and the inflammatory markers NF-κB and IL-1β. Additionally, it signified its antioxidant and antiapoptotic capacities by downregulating cleaved caspase-3 protein expression and curbing the content of malondialdehyde but boosted those of glutathione and Bcl-2. Aprepitant also downregulated the expression of miR-146a and turned off the endoplasmic reticulum (ER) stress cascade PERK/eIF-2α/ATF-4/CHOP. To recapitulate, aprepitant demonstrates a neuroprotective effect against DOX-mediated chemobrain by alleviating inflammatory, oxidative, and apoptotic responses, partly by reducing SP, ER stress, and miR-146a. These findings not only underscore the potential of aprepitant as a neuroprotective agent but also offer new understanding of the mechanisms behind chemobrain, leading to better therapeutic strategies for cancer patients.

148

项与阿瑞匹坦相关的新闻（医药）

2024-12-12

·药智网

这条赛道，仅恒瑞拥有1款活跃新药

抗肿瘤药物治疗，包括细胞毒药物化疗（以下简称化疗）、靶向治疗和免疫治疗等，可引起多种不良反应，最为常见的就是恶心和呕吐。用于预防或减少抗肿瘤药物所致恶心呕吐的治疗方法，成为恶性肿瘤患者支持疗法中的必要组成部分。目前，全球处于在研阶段的放化疗止吐药物以改良型新药为主，处于活跃状态的创新药仅恒瑞医药的HR-20013。注：本文仅作信息交流之目的，文中观点不代表药智网立场，也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。 01 放化疗止吐药研发动态目前，全球处于在研阶段的放化疗止吐药物以改良型新药为主，处于活跃状态的创新药仅HR-20013。 HR-20013：由恒瑞医药自主研发的HRS5580和帕洛诺司琼的复方制剂。其中HRS5580是创新分子，通过拮抗NK-1受体发挥止吐作用，半衰期长，具有高度的中枢神经系统渗透性，单药注射剂开发用于预防术后恶心和呕吐已获批临床。帕洛诺司琼是已上市使用的选择性5-HT3拮抗剂。HR-20013同时作用于5-HT3和NK-1受体，双途径抑制呕吐反射。其Ⅲ期临床试验结果显示，用于预防高致吐性化疗引起的恶心呕吐时，联合地塞米松具有可靠的疗效，且疗效在后续周期也有很好地保持。改良型新药聚焦于新复方制剂和新剂型的研发，例如BH006和LP-035。 BH006：贝海生物自主开发的全球首款福沙匹坦和帕洛诺司琼的固定复方制剂，同样作用于5-HT3和NK-1受体。相比传统的三药联用止吐方案，BH006每个疗程仅需注射给药1次，可减少给药次数，简化用药程序，从而提高患者依从性。 LP-035：力品药业（厦门）股份有限公司研发的盐酸帕洛诺司琼口颊膜，为中美首款进入临床阶段的口颊膜新型制剂。该制剂具有使用方便、依从性好等优点，有望为放化疗患者提供更便捷的治疗选择。 02 放化疗止吐药市场现状 2023年，中国放化疗止吐药市场销售额达47.76亿元，2019年-2023年5年复合增长率为-7.82%。目前总计有2个放化疗止吐药纳入国家集中采购，多个药物纳入省级集采，受价格大幅下降影响，市场销售额处于下降趋势，2023年销售额同比2022年下降8.37%。图1 中国放化疗止吐药总体市场规模及增速数据来源：药智数据，药智咨询整理目前，中国放化疗止吐药市场以5-羟色胺3受体拮抗剂（5-HT3 RA）为主导，该类药物产品多且临床疗效好，是多种放化疗止吐方案的首选药物。2023年，市场份额最大的是昂丹司琼，占比23.37%，其次是托烷司琼（占比20.48%）和帕洛诺司琼（占比8.13%）。尽管帕洛诺司琼因纳入国家集采而销售额大幅下降，但其作为新一代5-HT3 RA，在预防延迟性恶心呕吐方面显著优于第一代药物，因此预计市场需求依然会增长。 NK-1受体拮抗剂（NK-1 RA）的销售额和市场份额近年来呈增长趋势，以阿瑞匹坦和福沙匹坦为代表。这类药物通过竞争性抑制NK-1受体与P物质结合，有效预防延迟性恶心呕吐。随着临床应用的不断深入和新型复方制剂的研发上市，NK-1 RA的市场前景广阔。此外，糖皮质激素（如地塞米松）、非典型抗精神病药物（如奥氮平）和其他药物（如甲氧氯普胺）也在放化疗止吐药市场中占据一定份额。然而，这些药物通常作为辅助治疗或二线治疗使用，市场份额相对较小。 03 ANIV的分类及疾病特点抗肿瘤治疗所致恶心呕吐（AINV）根据抗肿瘤治疗方式，可分为化疗所致恶心呕吐（CINV）、靶向治疗及免疫治疗所致恶心呕吐（TIINV）和放疗所致恶心呕吐（RINV）。CINV和TIINV根据发生时间和治疗效果分为急性、延迟性、预期性、暴发性和难治性5类。化疗和靶向治疗及免疫治疗所致恶心呕吐的特点相似，急性恶心呕吐通常在化疗后24小时内发生，5-6小时达到高峰；延迟性恶心呕吐则发生在化疗24小时之后，48-72小时达到高峰，可持续6-7天。预期性恶心呕吐、暴发性恶心呕吐和难治性恶心呕吐则更多与患者的心理预期、治疗效果和既往病史相关。放疗所致恶心呕吐则可能在治疗后24小时内（急性期）或治疗结束后2-10天（延迟期）发生。 AINV的发生机制目前虽尚未完全明确，但已发现一些关键因素。化疗和靶向治疗及免疫治疗所致恶心呕吐的发生机制主要涉及外周途径和中枢途径，而放疗所致恶心呕吐则是多因素共同作用的结果。 04 疾病诊疗方案及治疗药物《中国肿瘤药物治疗相关恶心呕吐防治专家共识（2022年版）》提出，由于化疗所致恶心呕吐（CINV）最为严重、研究最为深入、疗效最为确切，其他抗肿瘤药物所致的恶心呕吐均参照CINV的原则处理。预防性止吐治疗是控制AINV的主要手段。预防性止吐方案基于抗肿瘤药物的致吐风险等级。根据未进行任何预防性处理时，单独使用某一抗肿瘤药物发生急性恶心呕吐的概率，致吐风险分为高度、中度、低度和轻微4个等级：表1 常用化疗药物致吐风险等级资料来源：《化疗所致恶心呕吐中西医诊治专家共识》，药智咨询整理注：本文仅作信息交流之目的，文中观点不代表药智网立场，也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。医师应根据既往使用止吐药物的经验和化疗方案的致吐风险分级选择不同类型的止吐药物，同时应对患者是否合并其他危险因素进行评估。联合应用抗肿瘤药物时，应基于致吐风险最高的药物来选择止吐药物。每个治疗周期前均应进行恶心呕吐风险的评估，根据风险评分情况及时调整治疗方案。专家共识推荐使用Dranitsaris评分系统个体化预测患者恶心呕吐的发生风险。抗肿瘤治疗所致恶心呕吐的治疗药物主要包括5-HT3受体拮抗剂、NK-1受体拮抗剂、糖皮质激素、非典型抗精神病药物等。根据患者恶心呕吐风险的评估结果，轻微和低风险患者使用单一止吐药物或不用，中风险患者使用二联止吐方案，高危患者使用三联甚至四联止吐方案。表2 AINV治疗药物分类及指南推荐情况资料来源：《中国肿瘤药物治疗相关恶心呕吐防治专家共识》，药智咨询整理注：本文仅作信息交流之目的，文中观点不代表药智网立场，也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。 05 结语尽管AINV的治疗药物众多，但临床未满足需求依然显著。尤其是TIINV和RINV等CINV以外的AINV种类，目前研究尚不充分，缺乏针对性的临床指南和专家共识。此外，国内外AINV临床实践对现有指南和准则的遵循情况也不尽如人意。化疗药持续时间与止吐药持续时间的不对等，更是给患者带来了诸多不便和副作用的风险。未来，随着新型药物的研发上市和临床应用的不断深入，我们有理由相信，AINV的治疗将更加精准、有效和便捷。同时，我们也期待更多的临床指南和专家共识能够出台，为AINV的规范化治疗提供有力支持。参考来源： [1]肖彩芝,王维,夏冬琴,等.化疗所致恶心呕吐中西医诊治专家共识[J].中国医院用药评价与分析,2023,23(12):1409-1415,1421. [2]张玉.化疗所致恶心呕吐的药物防治指南[J].中国医院药学杂志,2022,42(05):457-473. [3]Patel P,Robinson PD,Cohen M,et al.Prevention of acute and delayed chemotherapy-induced nausea and vomiting in pediatric cancer patients:A clinical practice guideline.Pediatr Blood Cancer.2022 Dec;69(12):e30001. [4]肿瘤药物治疗相关恶心呕吐防治中国专家共识（2019年版）[J].中国医学前沿杂志（电子版）,2019,11(11):16-26. [5]肿瘤治疗相关呕吐防治指南（2014版）[J].临床肿瘤学杂志,2014(3):263-273. [6]基于真实世界处方数据的化疗引起的恶心呕吐预防实践模式和止吐指南依从性-Aapro-2021-肿瘤学家-Wiley Online Library 声明：本内容为作者独立观点，不代表药智网立场。如需转载，请务必注明文章作者和来源。对本文有异议或投诉，请联系maxuelian@yaozh.com。责任编辑 | 史蒂文合作、投稿、转载开白 | 马老师 18323856316（同微信）如需定制医药咨询服务，请扫描下方二维码咨询！阅读原文，是受欢迎的文章哦

临床3期免疫疗法上市批准申请上市

2024-12-03

·PRNewswire

U.S. District Court Upholds Validity of CINVANTI® Patents

— Court Rules in Favor of Heron in Patent Lawsuit Against Fresenius Kabi USA, LLC — SAN DIEGO, Dec. 3, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the U.S. District Court for the District of Delaware ruled in Heron's favor in the Company's patent litigation against Fresenius Kabi USA, LLC with respect to CINVANTI® (aprepitant) injectable emulsion. The district court found that Heron's U.S. Patent Nos. 9,561,229 and 9,974,794, which expire in 2035, are valid and would be infringed by Fresenius' proposed generic product. The district court decision concludes the litigation initiated in July 2022 in response to Fresenius' submission of an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking approval of a generic version of CINVANTI®. As a result of the decision, Heron will seek an order from the Court prohibiting Fresenius from launching its generic CINVANTI® until after the expiration of the patents in 2035. This decision is subject to appeal. "We are pleased with this anticipated result of the proceeding and will continue to vigorously defend the CINVANTI® patent estate in the future," said Craig Collard, Chief Executive Officer of Heron. "The team at Heron takes great pride in the result of our successful history of developing injectable products, which is demonstrated by the strength of our intellectual property and the performance of our innovative drugs like CINVANTI® in serving patients with serious unmet needs." About Heron Therapeutics, Inc. Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit . Forward-looking Statements This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. Therefore, you should not place undue reliance on forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission, including under the caption "Risk Factors." Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law. Investor Relations and Media Contact: Ira Duarte Executive Vice President, Chief Financial Officer Heron Therapeutics, Inc. [email protected] 858-251-4400 SOURCE Heron Therapeutics, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

专利侵权专利到期

2024-11-29

·齐鲁制药集团

用科技表达我们的爱｜齐鲁制药3款产品新增纳入2024年国家医保目录

11月28日，国家医保局公布2024年国家医保药品目录调整结果，有91种药品新增进入国家医保药品目录。新版目录内药品总数增至3159种，平均降价63%，预计2025年将为患者减负超500亿元。新版国家医保药品目录将于2025年1月1日在全国范围内正式实施。本次目录调整，齐鲁制药共有注射用罗普司亭N01、氯苯唑酸葡胺软胶囊、二甲双胍恩格列净片（Ⅵ）3款目录外产品成功纳入医保，目录内产品伊鲁阿克片成功扩大医保支付范围。目前，齐鲁制药累计纳入国家医保的产品已有208个。 1 首款国产注射用罗普司亭成功纳入医保目录在此次目录更新中，齐鲁制药研发生产的第二代长效血小板生成素受体激动剂（TPO-RA），也是首款获批上市的国产注射用罗普司亭——注射用罗普司亭N01（瑞立升®）成功纳入国家医保目录。注射用罗普司亭N01适用于对其他治疗（例如皮质类固醇、免疫球蛋白）反应不佳的成人（≥18周岁）慢性原发免疫性血小板减少症（ITP）患者。作为第二代长效TPO受体激动剂，罗普司亭具有起效快，有效率高，给药频率低，用药方便、安全等特点，弥补了现有治疗药物的不足。瑞立升®此次被纳入新版医保目录，将进一步提升国内血小板减少相关疾病的药物可及性，为ITP患者提供了新的治疗选择。 2 创新药伊鲁阿克片新增适应症进入医保本次目录调整在肿瘤等重大疾病治疗领域，纳入了多个具有重要临床价值的创新药物。齐鲁制药伊鲁阿克片（启欣可®）继纳入2023版国家医保目录后，本次又有新适应症纳入国家医保，扩大了医保支付范围，由仅限于“限既往接受过克唑替尼治疗后疾病进展或对克唑替尼不耐受的间变性淋巴瘤激酶（ALK）阳性的局部晚期或转移性非小细胞肺癌（NSCLC）患者”调整为“限间变性淋巴瘤激酶（ALK）阳性的局部晚期或转移性非小细胞肺癌（NSCLC）患者”。这意味着伊鲁阿克全线覆盖ALK阳性局部晚期或转移性非小细胞肺癌患者，极大地减轻患者的经济负担。公司将进一步提升创新能力，快速推进创新药上市，并积极响应国家医药政策，不断提升药物的可及性，惠及更多患者。 3 罕见病药物纳入医保氯苯唑酸葡胺软胶囊惠及患者全球罕见病超过1万种，目前，只有不到5%的罕见病拥有针对性的治疗方案。本次调整新增的91种药品中，包含罕见病用药13个，齐鲁制药的氯苯唑酸葡胺软胶囊位列其中。齐鲁制药氯苯唑酸葡胺软胶囊为该产品国产首家获批上市，用于治疗成人转甲状腺素蛋白淀粉样变性多发性神经病（ATTR-PN）I期症状患者，可有效延缓周围神经功能损害。 ATTR-PN是一种罕见的遗传性、进行性加重、致死性疾病，30-40岁多发，且不可逆，严重危害患者生命。氯苯唑酸葡胺软胶囊原研产品于2020年在国内上市，治疗费用高昂。齐鲁制药勇于承担社会责任，积极探索解决罕见病患者用药的“最后一公里”障碍，在当年启动项目研发，于今年6月获得上市许可。氯苯唑酸葡胺软胶囊成功纳入医保，将大大降低ATTR-PN患者的经济负担，让更多罕见病患者得到更加规范的治疗。 4 累计208个产品进入国家医保目录持续助力健康中国建设在本次目录调整中，齐鲁制药二甲双胍恩格列净片（Ⅵ）也通过竞价进入医保，用于正在接受恩格列净和盐酸二甲双胍治疗的2型糖尿病成人患者，用于改善这些患者的血糖控制。在近几年的国家医保谈判中，齐鲁制药每年都有亮眼成绩：2022年，盐酸美金刚口溶膜等5个产品入选；2023年纳入伊鲁阿克片、孟鲁司特钠口溶膜、阿立哌唑口溶膜、阿瑞匹坦注射液等8个医保产品。目前，齐鲁制药已经有208个产品进入国家医保目录。齐鲁制药将继续秉持“大医精诚家国天下”的核心价值观，以解决目前未被满足的临床需求为导向，用“有温度的科技创新”，不断为健康中国建设添砖加瓦。撰稿：姜瑞丽、王颖、王亚楠、杨洪娟点击下方关键词获取更多资讯 ↓↓ | 李燕总裁 | 全国人大代表 | | 中国医药百强 | 伊鲁阿克 | | 雷珠单抗 | 全球首创艾托组合抗体 | 患者招募 | | 董事长的二十万个蛋糕 | 社会责任企业 |

上市批准申请上市

100 项与阿瑞匹坦相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02968	阿瑞匹坦	A04AD12	DB00673

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
术后恶心呕吐	欧盟	Merck Sharp & Dohme BV	2003-11-11
术后恶心呕吐	冰岛	Merck Sharp & Dohme BV	2003-11-11
术后恶心呕吐	列支敦士登	Merck Sharp & Dohme BV	2003-11-11
术后恶心呕吐	挪威	Merck Sharp & Dohme BV	2003-11-11
化疗引起的恶心和呕吐	美国	Merck & Co., Inc.	2003-03-26

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
生殖细胞和胚胎肿瘤	临床3期	美国	Merck Sharp & Dohme LLC	2007-12-01
乳腺癌	临床3期	-	Merck Sharp & Dohme Corp.	2002-12-01
恶心	临床3期	-	Merck Sharp & Dohme Corp.	2002-12-01
呕吐	临床3期	-	Merck Sharp & Dohme Corp.	2002-12-01
重度抑郁症	临床3期	-	Merck Sharp & Dohme Corp.	2001-09-01
痤疮样疹	临床2期	美国	Hoth Therapeutics, Inc.	2023-07-19
皮肤脂肪变性	临床2期	美国	Hoth Therapeutics, Inc.	2023-07-19
甲沟炎	临床2期	美国	Hoth Therapeutics, Inc.	2023-07-19
新型冠状病毒感染	临床2期	美国	Heron Therapeutics, Inc.	2020-07-20
晚期非小细胞肺癌	临床2期	中国	Merck Sharp & Dohme Corp.	2015-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ESMO_ASIA2024	N/A	-	150	Fosnetupitant + Palonosetron (FP)	構膚網願築醖醖廠憲範(鬱壓鏇顧顧餘繭廠選鏇) = 衊壓醖糧構鏇淵鏇廠廠鹹襯鏇範齋構襯願範構 (繭糧繭壓簾獵淵築簾艱 )	积极	2024-12-07
				Oral Aprepitant + Palonosetron (AP)	構膚網願築醖醖廠憲範(鬱壓鏇顧顧餘繭廠選鏇) = 糧構壓糧選繭顧憲願衊鹹襯鏇範齋構襯願範構 (繭糧繭壓簾獵淵築簾艱 )
ASCO2024	N/A	-	-	Fosaprepitant	膚憲襯憲窪遞獵選製鹽(製衊築鹹鬱鹽積構艱範) = 襯廠簾遞積艱積艱築齋壓範獵鹽醖廠壓鑰選繭 (蓋窪襯艱淵蓋憲廠築鹹 )	不佳	2024-05-24
NCT03435003 (CTgov)	临床4期	术后恶心呕吐 \| 呕吐	83	dexmedetomidine+Compazine+Total intravenous anesthesia+scopolamine transdermal+sugammadex+Reglan+Propofol+Fentanyl+Ondansetron+Aprepitant 80 mg Oral Capsule+Dexamethasone (Intervention Arm)	鏇觸選鹽製築遞夢顧構(簾構選遞鏇鏇製壓顧網) = 憲簾衊顧鬱鹹觸糧簾鏇網艱選艱繭鑰範遞餘艱 (壓鏇糧淵繭繭淵製蓋膚, 範遞範積獵鬱積齋鑰窪 ~ 鑰糧壓願鬱襯製糧製鹹) 更多	-	2024-02-14
				Compazine+sugammadex+Reglan+Sevoflurane+Desflurane+Ondansetron+Dexamethasone (Control Arm)	鏇觸選鹽製築遞夢顧構(簾構選遞鏇鏇製壓顧網) = 願鑰衊艱壓衊齋憲製網網艱選艱繭鑰範遞餘艱 (壓鏇糧淵繭繭淵製蓋膚, 積網醖鹽襯醖膚襯鑰簾 ~ 鏇糧鹹積齋簾鹽繭壓醖) 更多
NCT02939287 (CTgov)	临床3期	恶心 \| 呕吐	52	80 mg orally on Days 0 (Aprepitant)	選製鬱鏇襯醖鹹顧構選(淵餘顧醖網醖窪餘夢簾) = 壓淵糧範夢築選鹽製衊鹽襯選鏇夢獵窪鏇蓋積 (糧壓選齋齋鑰鹹簾範繭, 築範獵顧範衊鬱鹹鹽鬱 ~ 築餘築鏇鏇鬱鹹簾餘壓) 更多	-	2024-01-22
				+2 (Olanzapine)	選製鬱鏇襯醖鹹顧構選(淵餘顧醖網醖窪餘夢簾) = 齋範衊構衊憲鏇繭積夢鹽襯選鏇夢獵窪鏇蓋積 (糧壓選齋齋鑰鹹簾範繭, 範繭觸膚顧艱顧鏇壓蓋 ~ 糧蓋築願醖壓遞構範糧) 更多
NCT04873284 (Pubmed \| Transl Pediatr)	临床3期	化疗引起的恶心和呕吐	108	Intravenous fosaprepitant	襯顧鏇蓋齋廠壓廠蓋憲(鹽壓願壓鬱糧鏇簾膚憲) = 製齋選鹹餘觸選鏇鏇鬱築構觸夢築繭膚構壓憲 (遞選醖壓鑰築網艱鹹鑰 ) 更多	积极	2024-01-01
				Oral aprepitant	襯顧鏇蓋齋廠壓廠蓋憲(鹽壓願壓鬱糧鏇簾膚憲) = 襯獵窪觸憲艱糧願醖夢築構觸夢築繭膚構壓憲 (遞選醖壓鑰築網艱鹹鑰 ) 更多
NCT03237611 (CTgov)	临床2期	化疗引起的恶心和呕吐	15	Ondansetron 16 MG+Aprepitant 125 mg+Dexamethasone+Fosaprepitant 115 MG	繭網窪鹹蓋膚憲衊鬱繭(膚積願構製齋齋鑰鬱顧) = 艱築選遞構窪願鬱壓夢鏇獵繭夢構願膚觸憲遞 (鑰憲鏇鹽獵鑰壓鑰繭淵, 築獵顧顧鑰壓願繭範壓 ~ 鏇築廠鏇構鬱齋廠襯膚) 更多	-	2023-11-13
ESMO 12023 \| ESMO 22023 人工标引	临床2期	乳腺癌	76	Palonosetron+aprepitant+ olanzapine	襯糧願餘範獵鹹網廠鏇(鏇憲遞簾蓋鏇壓餘選鹽) = 醖網願範觸衊廠憲窪築網選網願憲網醖願糧製 (網衊齋鬱簾觸積壓鹹選, 9.4 ~ 27.5) 更多	不佳	2023-10-21
ESMO_ASIA2022	N/A	瘙痒 \| 肿瘤	36	Aprepitant	簾簾膚積鏇獵齋繭艱簾(窪顧鹹鏇廠願衊觸鏇憲) = 鹹獵鬱築鬱網鹽鹹觸築觸選簾鬱窪鏇積獵憲簾 (鑰構構範鹽鬱鏇壓鏇膚 )	-	2022-12-03
ESMO_ASIA2022	N/A	Substance P	36	Aprepitant	窪糧襯衊遞糧壓觸壓夢(淵觸糧窪選餘夢艱顧築) = 窪廠窪簾憲蓋鹽積襯膚鹹網選窪鏇鹽顧廠範簾 (鹽願糧窪淵齋鹽壓蓋鹹 )	-	2022-12-03
NCT02646020 (Pubmed) 人工标引	临床2期	瘙痒	130	aprepitant	範醖壓憲遞觸鏇膚積淵(夢製選窪膚艱鹹遞夢衊) = 鏇窪糧鑰鏇製獵餘簾繭壓觸鑰製壓鏇鑰壓夢憲 (鏇簾餘齋範蓋鏇願鏇廠 ) 更多	积极	2022-10-05
				desloratadine	範醖壓憲遞觸鏇膚積淵(夢製選窪膚艱鹹遞夢衊) = 艱艱壓壓築顧鬱襯窪窪壓觸鑰製壓鏇鑰壓夢憲 (鏇簾餘齋範蓋鏇願鏇廠 ) 更多